Biogen Inc. ($BIIB) Stock Forecast: Down 5.6% Today

What is Biogen Inc.?

Biogen (NASDAQ: BIIB) is a renowned biotechnology company known for its innovative treatments in neurology and rare diseases. Today, the stock experienced a significant bearish movement in the market.

Why is Biogen Inc. going down?

BIIB stock is down 5.6% on Mar 31, 2026 15:35

• The bearish movement in Biogen's stock price is possibly linked to the market's response to its acquisition of Apellis Pharmaceuticals for $5.6 billion. Concerns from analysts regarding the premium paid and competitive environment could be contributing to investor skepticism, despite the potential advantages of acquiring two approved medications and expertise in the nephrology sector.
• Biogen's strategic move to diversify its product portfolio and hasten the market entry of its new kidney disease drug, felzartamab, through the acquisition of Apellis Pharmaceuticals might be facing uncertainty from the market in terms of immediate financial impact and long-term growth prospects.
• The surge in Apellis Pharmaceuticals' stock value following the acquisition announcement presents a positive market sentiment toward the deal, contrasting with the volatility in Biogen's stock price. This disparity in market reactions between the two companies involved could be influencing Biogen's stock movement.
• Investors interested in Biogen are likely keeping a close watch on the company's future financial reports and strategic initiatives to evaluate the success of the acquisition and its potential effects on Biogen's overall performance in upcoming quarters.

BIIB Price Chart

BIIB Technical Analysis

BIIB News

Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy

Biogen has acquired Apellis Pharmaceuticals for $5.6 billion, a move that provides Biogen with two approved medicines and critical expertise in the nephrology space. This acquisition is expected to give Biogen a "running start" for the future launch of its own kidney disease asset, felzartamab, which is currently in multiple Phase 3 trials. Despite concerns from analysts about the premium paid and competitive dynamics, Biogen believes the deal will diversify its portfolio and accelerate the market entry of its new kidney disease drug.

https://www.biospace.com/business/biogen-secures-running-start-in-kidney-disease-with-5-6b-apellis-buy

Chubb will release Q1 results after market close on April 21

Chubb Limited (NYSE: CB) announced it will host its first-quarter earnings conference call on Wednesday, April 22, 2026, at 8:30 a.m. Eastern. The company plans to release its Q1 earnings and financial supplement after the market closes on Tuesday, April 21, 2026. Interested parties can access the live webcast or dial-in using provided numbers; a replay will also be available online.

https://www.stocktitan.net/news/CB/chubb-limited-to-hold-its-first-quarter-earnings-conference-call-on-996l1q6tcvwk.html

KKR and Taiyo Holdings Agree to Privatization to Accelerate Long-Term Growth

KKR is acquiring Taiyo Holdings through a tender offer at JPY 4,750 per share, representing a significant premium over recent market prices. Taiyo Holdings, a manufacturer of electronic materials and a medical/pharmaceutical business, seeks privatization to accelerate its long-term growth strategy by focusing on growth opportunities in AI, data centers, and expanding its contract manufacturing. KKR's deep sector experience and global network are expected to support Taiyo Holdings' strategic initiatives.

https://www.stocktitan.net/news/KKR/kkr-and-taiyo-holdings-agree-to-privatization-to-accelerate-long-h184u46fafdi.html

Why Is Apellis Stock Skyrocketing Tuesday? - Apellis Pharmaceuticals (NASDAQ:APLS), Biogen (NASDAQ:BIIB)

Apellis Pharmaceuticals' stock is skyrocketing after Biogen announced its intent to acquire the company for $41 per share in cash, totaling approximately $5.6 billion. This acquisition is expected to bolster Biogen's immunology and rare disease portfolio, particularly with Apellis's FDA-approved therapies Empaveli and Syfovre, which generated $689 million in combined net sales in 2025. The deal includes a contingent value right for Apellis shareholders and is projected to enhance Biogen's revenue and adjusted earnings per share starting in 2027.

https://www.benzinga.com/m-a/26/03/51569831/biogen-lands-two-fast-growing-drugs-in-blockbuster-apellis-deal

Eightco Holdings Inc. (NASDAQ: ORBS) outlines $326M AI and crypto treasury mix

Eightco Holdings Inc. (NASDAQ: ORBS) has reported total holdings of approximately $326 million as of March 30, 2026, comprising significant investments in Worldcoin (WLD) and Ethereum (ETH), along with a $90 million stake in OpenAI and $25 million in Beast Industries. The company aims to provide public investors exposure to leading private technology companies in AI, digital identity, and next-generation consumer platforms. This strategy is supported by $130 million in recent funding commitments from investors like Bitmine Immersion Technologies, ARK Invest, and Payward.

https://www.stocktitan.net/sec-filings/OCTO/8-k-eightco-holdings-inc-reports-material-event-9bc49b922c79.html

Trending Today

Biogen Inc. Price History

31.02.2026 - BIIB Stock was down 5.6%

• The bearish movement in Biogen's stock price is possibly linked to the market's response to its acquisition of Apellis Pharmaceuticals for $5.6 billion. Concerns from analysts regarding the premium paid and competitive environment could be contributing to investor skepticism, despite the potential advantages of acquiring two approved medications and expertise in the nephrology sector.
• Biogen's strategic move to diversify its product portfolio and hasten the market entry of its new kidney disease drug, felzartamab, through the acquisition of Apellis Pharmaceuticals might be facing uncertainty from the market in terms of immediate financial impact and long-term growth prospects.
• The surge in Apellis Pharmaceuticals' stock value following the acquisition announcement presents a positive market sentiment toward the deal, contrasting with the volatility in Biogen's stock price. This disparity in market reactions between the two companies involved could be influencing Biogen's stock movement.
• Investors interested in Biogen are likely keeping a close watch on the company's future financial reports and strategic initiatives to evaluate the success of the acquisition and its potential effects on Biogen's overall performance in upcoming quarters.

31.02.2026 - BIIB Stock was down 5.0%

• Biogen's bearish movement today could be attributed to the announcement of its acquisition of Apellis Pharmaceuticals for $5.6 billion. While acquisitions are often seen as a strategic move to expand the company's portfolio, the market may have reacted negatively due to concerns about the integration process and the potential impact on Biogen's financials.
• The news of Stryker promoting key finance executives may have also influenced investor sentiment, as leadership changes within a company can sometimes create uncertainty about future financial strategies and performance.
• Additionally, the overall market sentiment towards biotech stocks and the broader economic conditions could have contributed to the bearish movement in Biogen's stock today. Investors may be cautious amid market volatility and global economic uncertainties.

31.02.2026 - BIIB Stock was down 5.2%

• Biogen's stock experienced a bearish movement as the market reacted negatively to the news of its intent to acquire Apellis Pharmaceuticals for $5.6 billion.
• The acquisition is seen as a strategic move to enhance Biogen's immunology and rare disease portfolio with Apellis's FDA-approved therapies, but investors may have concerns about the hefty price tag and potential integration challenges.
• The market might be cautious about the impact of this acquisition on Biogen's financials, revenue, and adjusted earnings per share starting in 2027, leading to the bearish trend.
• Investors are likely monitoring how Biogen navigates this acquisition and integrates Apellis's assets into its existing portfolio to gauge the long-term impact on the company's growth prospects.

27.02.2026 - BIIB Stock was down 2.5%

• The decline in Biogen's stock value possibly stemmed from Vanguard's recent disclosure of holding zero shares and beneficial ownership of Biogen. This change in investment interest could have prompted investor apprehension, leading to a sell-off.
• Positive growth predictions in the Anca Vasculitis Drug Market and emerging therapies in the Spinal Muscular Atrophy Pipeline might have momentarily diverted investor attention from Biogen, negatively affecting its stock performance.
• The financial outcomes and strategic advancements reported by MapLight Therapeutics, such as upcoming Phase 2 study outcomes, may have redirected investor focus towards other biotech firms, influencing Biogen's stock downward.
• Although the collaboration between Biogen and Alteogen Inc. presented optimistic prospects for Biogen, it might not have sufficed to counter prevailing market sentiments and incite a bullish upturn in the stock on the given day.

06.01.2026 - BIIB Stock was up 2.4%

• BIIB stock surged today, hitting a 52-week high at $190.34, marking a 31.14% rise in the past year and a 43.31% gain in the last six months.
• The positive market response follows Biogen's strong Q4 2025 financial performance, surpassing revenue projections and beating analyst estimates for non-GAAP EPS.
• Biogen's strategic focus on its at-home Alzheimer’s drug, successful trial outcomes for multiple treatments, and receipt of FDA Breakthrough Therapy Designation have boosted investor confidence in the company's future growth prospects.
• Despite revenue challenges from declining multiple sclerosis treatments, Biogen's optimistic 2026 outlook, emphasis on neurodegenerative and rare diseases, and favorable valuation based on financial metrics have bolstered investor trust and fueled the stock's upward trajectory.

06.01.2026 - BIIB Stock was up 6.9%

• Biogen's stock demonstrated significant upward momentum, reaching a 52-week high, following the release of impressive fourth-quarter earnings and revenues, attributed to the notable sales growth of its Alzheimer's medication Leqembi.
• The company's strategic shift from a primary emphasis on multiple sclerosis to establishing itself as a key player in neuro-innovation, with successful treatments like Skyclarys and Leqembi, has amplified investor confidence and positively impacted the stock's performance.
• Biogen's perceived undervaluation, evidenced by a P/E ratio of 16.92 and a robust free cash flow yield of 8%, alongside favorable developments such as FDA recognitions and successful trial outcomes, has further bolstered the optimistic outlook surrounding the stock.
• Biogen's adept navigation of obstacles, including regulatory complexities and market competition, in conjunction with its growth-oriented approach through collaborations and a diversified product pipeline, highlights its potential for long-term success in the dynamic biopharmaceutical sector.

06.01.2026 - BIIB Stock was up 5.3%

• Despite a decrease in revenue from multiple sclerosis treatments, Biogen posted strong financial results for Q4 and full year 2025, thanks to growth products such as LEQEMBI, SKYCLARYS, and ZURZUVAE.
• Investors reacted positively to the company's overall performance and growth in newer products, leading to a bullish movement in the stock despite the decline in revenue from multiple sclerosis treatments.
• Biogen's emphasis on expanding its pipeline through acquisitions and collaborations, as well as achieving important regulatory milestones, has instilled optimism among investors despite challenges in its multiple sclerosis product portfolio.
• The market movement demonstrates investor trust in Biogen's capability to navigate competition, regulatory changes, and operational risks while fostering growth through innovative products and strategic initiatives.

25.01.2026 - BIIB Stock was down 2.5%

• The downward trend in BIIB's stock price today may be linked to a trade secrets lawsuit and a dismissal motion filed by Definium Therapeutics Inc., resulting in uncertainty and legal concerns.
• Market sentiment could also be influenced by the struggles of other biotech firms such as Avidity Biosciences, which reported significant financial losses, leading to doubts about the sector's financial performance and future growth.
• Furthermore, the FDA's rejection of Alvotech's biologics license application due to facility issues and the subsequent legal investigation could have raised apprehensions about regulatory challenges in the biotech industry, impacting attitudes towards companies like BIIB.

14.00.2026 - BIIB Stock was down 5.3%

• The downward movement in Biogen's stock is likely due to expected expenses in the fourth quarter related to in-process research and development (IPR&D) and milestone payments, impacting earnings per share.
• Despite introducing Leqembi and exploring new Alzheimer's treatments, the market response is pessimistic towards the predicted financial changes and costs.
• Analysts, including Bank of America Securities' Hold rating, may be influencing the bearish outlook as investors evaluate the company's financial prospects alongside its strategic goals and product advancements.

14.00.2026 - BIIB Stock was down 5.8%

• Biogen expects a significant impact on its fourth-quarter earnings per share due to in-process research and development (IPR&D) charges, leading to a negative investor sentiment.
• Analysts from Bank of America Securities and other firms hold mixed views on Biogen, resulting in differing ratings and price targets that have added to the uncertainty surrounding the stock.
• The European Commission's approval of a high-dose SPINRAZA regimen for spinal muscular atrophy has the potential to strengthen Biogen's investment outlook. However, concerns about managing pricing pressures on high-cost therapies may have influenced the stock negatively.
• The market's response to Biogen's financial adjustments and upcoming drug launches underscores the need to balance innovation with financial performance in the biotech sector, impacting investor sentiment and stock movement.

14.00.2026 - BIIB Stock was down 6.0%

• Today's downturn in BIIB stock is linked to an anticipated impact of about $1.26 per share on earnings due to research and development charges in the fourth quarter.
• Despite efforts to enhance its presence in the Alzheimer's market with product launches and research endeavors, the financial adjustments appear to have dampened investor confidence.
• Contributing to the bearish sentiment could be analyst ratings like the Hold recommendation from Bank of America Securities, creating uncertainty among investors due to varying opinions.
• The stock's negative performance today reflects a market reaction influenced by financial implications and analyst assessments, despite Biogen's ongoing advancements in its pipeline and infrastructure.

06.00.2026 - BIIB Stock was up 5.8%

• BIIB stock surged as Bank of America Securities reiterated a Hold rating with a price target of $189.00, indicating stability and potential growth.
• Anticipation of regulatory progress in international markets, especially in China, for their Alzheimer's treatment formulations, like Leqembi, contributed to the positive market sentiment.
• The acceptance of the Biologics License Application for the subcutaneous formulation of LEQEMBI® for early Alzheimer's disease in China by the National Medical Products Administration was a significant catalyst for the stock's rise.
• The market's positive reaction reflects investors' optimism towards BIIB's innovative treatments and potential expansion into new markets, such as China, driving the stock's bullish movement.